OncoLink Cancer Treatment and Resources

Menopausal Estrogen and Estrogen-Progestin Replacement Therapy and Breast Cancer Risk

Catherine Schairer, Jay Lubin, Rebecca Troisi, et al
Abramson Cancer Center of the University of Pennsylvania
Last Modified: November 1, 2001

Reviewers: Li Liu, MD
Source: JAMA, volume 283, No. 4: 485-491, (January) 2000

Introduction

Postmenopausal estrogen therapy has been used widely to reduce menopausal symptoms, risk of osteoporotic fractures, and probably coronary heart disease. Side effects include venous thrombosis and cancers of breast and uterus. Combination therapy of estrogen and progestin has become the standard hormonal regimen for women with a uterus to prevent an increased risk of endometrial hyperplasia and carcinoma. This study addressed the risk of breast cancer associated with the use of estrogen-progestin hormone replacement therapy (HRT).

Methods

Follow-up data on 46,355 postmenopausal women in the Breast Cancer Detection Demonstration Project from 1980 to 1995 was collected.

Results

After adjusting for age, education, body mass index, history of mammography and age at menopause, compared with women who had not taken HRT:

  • the relative risk of breast cancer was 1.4 in women who took combination HRT either currently or within the previous 4 years.
  • the relative risk was 1.2 for women who had recently used estrogen-only therapy.
  • the relative risk of breast cancer increased by 1% for each year of estrogen-only use and by 8% for each year of estrogen-progestin-only use.

Discussion

This study suggested that current or recent use of HRT is associated with a greater increased risk of breast cancer than estrogen-only therapy. The investigators indicated that the study is not the final word on the topic of HRT and breast cancer risk. More studies evaluating longer-term use of estrogen in combination with progestin and different combination regimens of hormones are needed in the future. Decisions for women and their physicians should be made based on the individual considerations.

OncoLink I wish u knew...

Ms. Schafer discusses the role of the chaplain and spirituality in cancer care. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS